PubMed COVID-19 Clinical Care

No abstract

This study analyzes the impact of COVID-19 variants on cost-effectiveness across age groups, considering vaccination efforts and nonpharmaceutical interventions in Republic of Korea. We aim to assess the costs needed to reduce COVID-19 cases and

CONCLUSION: The activity domain measures demonstrated efficiency in identifying participation rates and change. CBOs may deem them useful for assessing support and service needs to facilitate participation.

No abstract

Paxlovid is a recent FDA approved specific drug for COVID-19. Extensive prescription of Paxlovid could induce potential synthetic cytotoxicity with drugs. Herein, we aimed to examine pairwise synthetic cytotoxicity between Paxlovid and 100 frequently

CONCLUSIONS: While there was an increase in new households to the food pantry, overall utilization did not increase.

The COVID-19 pandemic has exposed concerns around life span and aging, but these tensions and anxieties around longevity are not new. Physicians, scientists, and philosophers have been meditating on the idea and consequences of life extension for

CONCLUSION: Leveraging COVID-19 inspired collaborations, technologies and avenues for health service delivery is an opportunity to maximise benefits for the TB programme. Reinvestment in national TB programmes and political prioritisation of TB are

CONCLUSION: In STEMI patients treated with different P2Y12 inhibitors, there was no significant difference in mortality, bleeding, stroke, and thrombotic complications, regardless of the presence or absence of COVID-19 infection.

Former meta-analyses concluded that there was not sufficient evidence to determine the effect of surgical masks and N95 respirators. We collected randomized controlled trials (RCTs) and conducted a systematic review and meta-analysis to evaluate the